dr. T. van Meerten

Research

Publications
  1. Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?

    Bouwstra, R., van Meerten, T. & Bremer, E., 1-Jan-2019, In : Molecular and Cellular Oncology. 6, 3, 1600349.

    Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

  2. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting

    van der Galien, H. T., Hoogendoorn, M., Kibbelaar, R. E., van Meerten, T. & van Rijn, R. S., Jan-2019, In : Annals of Oncology. 30, 1, p. 151-152 2 p.

    Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

  3. CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

    Van Meerten, T., Bouwstra, R., He, Y., Janneke, D. B., Kooistra, H., Fehrmann, R., Ammatuna, E., Huls, G. & Bremer, E., 29-Nov-2018, In : Blood. 132, Suppl.1, 3 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  4. Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis

    He, Y., Bouwstra, R., Wiersma, V. R., de Jong, M., Lourens, H. J., Fehrmann, R., de Bruyn, M., Ammatuna, E., Huls, G., van Meerten, T. & Bremer, E., 1-Feb-2019, In : Nature Communications. 10, 1, 8 p., 533.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (14) »

View graph of relations

ID: 50288891